The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The neurofibromatosis type 1 gene encodes a protein related to GAP
Abstract
cDNA walking and sequencing have extended the open reading frame for the neurofibromatosis type 1 gene (NF1). The new sequence now predicts 2485 amino acids of the NF1 peptide. A 360 residue region of the new peptide shows significant similarity to the known catalytic domains of both human and bovine GAP (GTPase activating protein). A much broader region, centered around this same 360 amino acid sequence, is strikingly similar to the yeast IRA1 product, which has a similar amino acid sequence and functional homology to mammalian GAP. This evidence suggests that NF1 encodes a cytoplasmic GAP-like protein that may be involved in the control of cell growth by interacting with proteins such as the RAS gene product. Mapping of the cDNA clones has confirmed that NF1 spans a t(1;17) translocation mutation and that three active genes lie within an intron of NF1, but in opposite orientation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS proteins primarily bind to guanosine diphosphate (GDP) and are in an inactive conformation maintained by intrinsic guanosine triphosphate (GTP) hydrolytic activity.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [9]
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
Feinberg, A. P., & Vogelstein, B. (1983) · Analytical Biochemistry · doi:10.1016/0003-2697(83)90418-9 · Cited by 24,512
A simple method for displaying the hydropathic character of a protein
Kyte, J., & Doolittle, R. F. (1982) · Journal of Molecular Biology · doi:10.1016/0022-2836(82)90515-0 · Cited by 22,927
A comprehensive set of sequence analysis programs for the VAX
Devereux, J., Haeberli, P. E., & Smithies, O. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.1part1.387 · Cited by 14,222
Improved tools for biological sequence comparison.
Pearson, W. R., & Lipman, D. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.8.2444 · Cited by 11,227
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90381-6 · Cited by 4,952
Screening λgt Recombinant Clones by Hybridization to Single Plaques in Situ
Benton, W. D., & Davis, R. W. (1977) · Science · doi:10.1126/science.322279 · Cited by 4,520
Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs
Kozak, M. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.2.857 · Cited by 3,259
[5] Rapid and sensitive sequence comparison with FASTP and FASTA
Pearson, W. R. (1990) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(90)83007-v · Cited by 1,934
Type 1 Neurofibromatosis Gene: Identification of a Large Transcript Disrupted in Three NF1 Patients
Wallace, M. R., Marchuk, D. A., Andersen, L. B., Letcher, R., Odeh, H. M., Saulino, A. M., Fountain, J. W., Brereton, A., Nicholson, J. M., Mitchell, A. L., et al. (1990) · Science · doi:10.1126/science.2134734 · Cited by 1,478
Research works printed but not linked: 1
- Stumpf, 1987, Neurofibromatosis, Arch. Neurol., 45, 575
Cited by
Sorted by citations
Items 101–200 of 1,000
Neurofibromin: a general outlook
Trovó-Marqui, A. B., & Tajara, E. H. (2006) · Clinical Genetics · doi:10.1111/j.1399-0004.2006.00639.x · Cited by 201
Gallouzi, I., Parker, F., Chébli, K., Maurier, F., Labourier, E., Barlat, I., Capony, J., Tocqué, B., & Tazi, J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3956 · Cited by 201
Williams syndrome: From genotype through to the cognitive phenotype
Donnai, D., & Karmiloff‐Smith, A. (2000) · American Journal of Medical Genetics · doi:10.1002/1096-8628(200022)97:2 · Cited by 314
TP53 mutations are frequent in malignant NFI tumors
Legius, E., Dierick, H. A., Wu, R., Hall, B. K., Marynen, P., Cassiman, J., & Glover, T. W. (1994) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870100405 · Cited by 195
Retroviral insertional mutagenesis as a strategy to identify cancer genes
Jonkers, J., & Berns, A. J. M. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00020-g · Cited by 194
Kinoshita, K., Hirota, S., Isozaki, K., Ohashi, A., Nishida, T., Kitamura, Y., Shinomura, Y., & Matsuzawa, Y. (2003) · The Journal of Pathology · doi:10.1002/path.1487 · Cited by 193
“NF1 gene product, neurofibromin, is a member of the GAP family of ras regulatory proteins [19].”
BackgroundAnderson, J. L., & Gutmann, D. H. (2015) · Handbook of clinical neurology · doi:10.1016/b978-0-444-62702-5.00004-4 · Cited by 193
The NF1 gene revisited - from bench to bedside
Yap, Y. S., McPherson, J. R., Ong, C. K., Rozen, S., Teh, B. T., Lee, A. S. G., & Callen, D. F. (2014) · Oncotarget · doi:10.18632/oncotarget.2194 · Cited by 189
“Its product neurofibromin is an important negative regulator of Ras cellular proliferation pathways [3-7].”
BackgroundThe Concept of the Gene: Short History and Present Status
Portin, P. (1993) · The Quarterly Review of Biology · doi:10.1086/418039 · Cited by 194
“Yanofsky (1963) and Yanofsky et al.”
Ras proteins in the control of the cell cycle and cell differentiation
Crespo, P., & León, J. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000645 · Cited by 190
Foster, K. W., Ren, S., Louro, I. D., Lobo-Ruppert, S. M., McKie-Bell, P., Grizzle, W. E., Hayes, M., Broker, T. R., Chow, L. T., & Ruppert, J. M. (1999) · PubMed · Cited by 187
Gröb, T., Seybert, G., Massa, W., Weller, F., Palaniswami, R., Greiner, A., & Dehnicke, K. (2000) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20001201)39:23 · Cited by 33
Ras and relatives—job sharing and networking keep an old family together
Ehrhardt, A., Ehrhardt, G. R. A., Guo, X., & Schrader, J. W. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00904-9 · Cited by 184
“Four other GAPs, the product of the neurofibromatosis gene Nf1, GAP1m and its close homolog GAPIII, and GAP1(IP4BP) (also known as R-Ras GAP), have been described [60–63].”
BackgroundPlexiform neurofibromas in NF1
Packer, R. J., Gutmann, D. H., Rubenstein, A. E., Viskochil, D. H., Zimmerman, R. A., Vézina, G., Small, J., & Korf, B. R. (2002) · Neurology · doi:10.1212/wnl.58.10.1461 · Cited by 185
Self-citationDo occupational factors influence the risk of colon and rectal cancer in different ways?
Arbman, G., Axelson, O., Fredriksson, M. G., Nilsson, E., & Sjödahl, R. I. (1993) · Cancer · doi:10.1002/1097-0142(19931101)72:9 · Cited by 55
Lakkis, M. M., & Epstein, J. A. (1998) · Development · doi:10.1242/dev.125.22.4359 · Cited by 183
Medema, R. H., de Vries-Smits, A. M. M., van der Zon, G. C. M., Maassen, J. A., & Bos, J. L. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.155-162.1993 · Cited by 183
“Two GAPs have been identified in mammalian cells: p120GAP (48) and the product of the neurofibromatosis type 1 gene, neurofibromin (1, 33, 52).”
Neurofibromin Structure, Functions and Regulation
Bergoug, M., Doudeau, M., Godin, F., Mosrin-Huaman, C., Vallée, B., & Bénédetti, H. (2020) · Cells · doi:10.3390/cells9112365 · Cited by 182
“In addition, a 360 amino-acid portion of neurofibromin appears to be homologous to the catalytic domains of IRA gene products and mammalian p120GAP (GTPase-activating protein), suggesting that neurofibromin possesses a RasGAP function [19].”
BackgroundIngram, D. A., Yang, F., Travers, J. B., Wenning, M. J., Hiatt, K. K., New, S., Hood, A. F., Shannon, K., Williams, D. A., & Clapp, D. W. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.1.181 · Cited by 181
“Neurofibromin, the protein encoded by neurofibromatosis type 1 (NF1), negatively regulates Ras output by accelerating the conversion of Ras-GTP to Ras-GDP (1, 2).”
BackgroundInfluentialGrand, R. J. A., & Owen, D. (1991) · Biochemical Journal · doi:10.1042/bj2790609 · Cited by 181
Structural analysis of the GAP‐related domain from neurofibromin and its implications
Scheffzek, K., Ahmadian, M. R., Wiesmüller, L., Kabsch, W., Stege, P., Schmitz, F., & Wittinghofer, A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.15.4313 · Cited by 181
“Xu,G. et al. (1990a) The neurofibromatosis type 1 gene encodes a protein related to GAP.”
Scheffzek, K., Lautwein, A., Kabsch, W., Ahmadian, M. R., & Wittinghofer, A. (1996) · Nature · doi:10.1038/384591a0 · Cited by 173
Andersen, L. B., Ballester, R., Marchuk, D. A., Chang, E. C., Gutmann, D. H., Saulino, A. M., Camonis, J., Wigler, M. H., & Collins, F. S. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.487-495.1993 · Cited by 172
Allelotype study of primary hepatocellular carcinoma.
Fujimori, M., Tokino, T., Hino, O., Kitagawa, T., Imamura, T., Okamoto, E., Mitsunobu, M., Ishikawa, T., Nakagama, H., & Harada, H. (1991) · PubMed · Cited by 170
The neurofibromatosis type 1 gene and its protein product, neurofibromin
Gutmann, D. H., & Collins, F. S. (1993) · Neuron · doi:10.1016/0896-6273(93)90324-k · Cited by 168
“…of the predicted protein sequenceof the NF7 gene product, termed neurofibromin, revealed sequence similarity between neurofibromin and various members of the GTPase-activating protein (GAP) superfamily (Figure 3) (Xu et al., 1990a, 1990b; Martin et al., 1990; Ballester et al., 1990).”
Lau, N. C., Feldkamp, M. M., Roncari, L., Loehr, A., Shannon, P. T., Gutmann, D. H., & Guha, A. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.9.759 · Cited by 172
“NF1 patients harbor germline mutations in 1 copy of the NF1 gene on chromosome 17 (2).”
BackgroundInfluentialMachine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas
Way, G. P., Sánchez-Vega, F., La, K., Armenia, J., Chatila, W. K., Luna, A., Sander, C., Cherniack, A. D., Mina, M., Ciriello, G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.046 · Cited by 172
“When the pathway is activated, often by gain-of-function KRAS, NRAS, or HRAS mutations or through NF1 loss-of-function events, cells increase their translational output, and unchecked cellular proliferation occurs (McCormick, 1989; Xu et al., 1990).”
BackgroundThe human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer.
Sato, T., Saito, H., Swensen, J. J., Olifant, A., Wood, C., Danner, D. B., Sakamoto, T., Takita, K.-I., Kasumi, F., & Miki, Y. (1992) · PubMed · Cited by 164
Kalra, R., Paderanga, D., Olson, K., & Shannon, K. (1994) · Blood · doi:10.1182/blood.v84.10.3435.3435 · Cited by 162
Cimino, P. J., & Gutmann, D. H. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64076-5.00051-x · Cited by 161
Loss of neurofibromatosis 1 (NF1) gene expression in NF1‐associated pilocytic astrocytomas
Gutmann, D. H., Donahoe, J. S., Brown, T., James, C. D., & Perry, A. (2000) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2000.00258.x · Cited by 161
Ferner, R. E., & O'Doherty, M. J. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200212000-00004 · Cited by 161
Orthopaedic Manifestations of Neurofibromatosis in Children: An Update
Vitale, M. G., Guha, A., & Skaggs, D. L. (2002) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200208000-00013 · Cited by 160
A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1Preprint
Stowe, I. B., Mercado, E. L., Stowe, T. R., Bell, E. L., Osés-Prieto, J. A., Hernández, H., Burlingame, A. L., & McCormick, F. P. (2012) · Genes & Development · doi:10.1101/gad.190876.112 · Cited by 158
Neurofibromatosis: Past, Present, and Future
Riccardi, V. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105023241812 · Cited by 159
Juvenile myelomonocytic leukemia: who’s the driver at the wheel?
Niemeyer, C. M., & Flotho, C. (2019) · Blood · doi:10.1182/blood-2018-11-844688 · Cited by 157
A gene for Hirschsprung disease (megacolon) in the pericentromeric region of human chromosome 10
Angrist, M. H., Kauffman, E., Slaugenhaupt, S. A., Matise, T. C., Puffenberger, E. G., Washington, S. S., Lipson, A., Cass, D. T., Reyna, T. M., Weeks, D. E., et al. (1993) · Nature Genetics · doi:10.1038/ng0893-351 · Cited by 157
Dasgupta, B., Dugan, L. L., & Gutmann, D. H. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08949.2003 · Cited by 155
“Based on the presence of a 300 amino acid residue RAS GTPase-activating protein (GAP)related domain (NF1GRD), neurofibromin growth regulation has been hypothesized to reflect its ability to function as a RAS- GAP (Ballester et al., 1990; Martin et al., 1990; Xu et al., 1990).”
BackgroundMalignant Peripheral Nerve Sheath Tumors
Gupta, G., Mammis, A., & Maniker, A. H. (2008) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2008.07.004 · Cited by 155
“One of the functions of neurofibromin is to reduce cell proliferation by accelerating the inactivation of the proto-oncogene p21-ras, which has a pivotal role in mitogenic intracellular signaling pathways.(41) Patients who have MPNSTs demonstrate aberrations in 17q 11.”
BackgroundMutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines
Andersen, L. B., Fountain, J. W., Gutmann, D. H., Tarlé, S. A., Glover, T. W., Dracopoli, N. C., Housman, D. E., & Collins, F. S. (1993) · Nature Genetics · doi:10.1038/ng0293-118 · Cited by 155
Neurofibromatosis type 1 gene mutations in neuroblastoma
The, I., Murthy, A. E., Hannigan, G. E., Jacoby, L. B., Menon, A. G., Gusella, J. F., & Bernards, A. (1993) · Nature Genetics · doi:10.1038/ng0193-62 · Cited by 155
Loss of NF1 alleles in phaeochromocytomas from patients with type 1 neurofibromatosis
Xu, W., Mulligan, L. M., Ponder, M. A., Liu, L., Ponder, B. A. J., Smith, B. A., & Mathew, C. G. (1992) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870040411 · Cited by 155
Zhang, Y.-Y., Vik, T. A., Ryder, J. W., Srour, E. F., Jacks, T., Shannon, K., & Wade Clapp, D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1893 · Cited by 150
NF1 Gene Mutations Represent the Major Molecular Event Underlying Neurofibromatosis-Noonan Syndrome
Luca, A. D., Bottillo, I., Sárközy, A., Carta, C., Neri, C., Bellacchio, E., Schirinzi, A., Conti, E., Zampino, G., Battaglia, A., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/498454 · Cited by 153
“sible for all cases of NF1 (Xu et al. 1990).”
BackgroundEpidemiology and therapies for metastatic sarcoma
Reed, D. R., Amankwah, & Conley, A. P. (2013) · Clinical Epidemiology · doi:10.2147/clep.s28390 · Cited by 154
Vogel, K. S., Brannan, C. I., Jenkins, N. A., Copeland, N. G., & Parada, L. F. (1995) · Cell · doi:10.1016/0092-8674(95)90470-0 · Cited by 153
An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin).
Tikoo, A., Varga, M., Ramesh, V., Gusella, J. F., & Maruta, H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31525-9 · Cited by 151
The management of brainstem gliomas in patients with neurofibromatosis 1
Pollack, I. F., Shultz, B. L., & Mulvihill, J. J. (1996) · Neurology · doi:10.1212/wnl.46.6.1652 · Cited by 150
“We subdivided the imaging features of these lesions into four groups: (1) diffuse enlargement of the brainstem with hypointensity on T,-weighted MR images and hyperintensity on T,-weighted images (n = 9); (2) focal enhancing masses (n = 7); (3) intrinsic tectal tumors (n = 5); and (4) focal nonenhancing areas of hypoi…”
BackgroundMethodSomatic NF1 inactivation is a frequent event in sporadic pheochromocytoma
Burnichon, N., Buffet, A., Parfait, B., Letouzé, É., Laurendeau, I., Loriot, C., Pasmant, É., Abermil, N., Valeyrie‐Allanore, L., Bertherat, J. Y., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds374 · Cited by 159
“The GRD central domain of the protein is coded by exons 20–27a (50).”
BackgroundNeurofibromatosis Type 1 Due to Germ-Line Mosaicism in a Clinically Normal Father
Lázaro, C., Ravella, A., Gaona, A., Volpini, V., & Estivill, X. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411243312102 · Cited by 147
Izquierdo, M., Downward, J., Graves, J. D., & Cantrell, D. A. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.7.3305-3312.1992 · Cited by 150
Pathophysiology of Neurofibromatosis Type 1
Theos, A. J., & Korf, B. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-11-200606060-00010 · Cited by 146
“Neurofibromin includes a guanosine triphosphatase (GTPase)–activating protein (GAP) (see Glossary) domain (18).”
Yantiss, R. K., Rosenberg, A. E., Sarran, L., Besmer, P., & Antonescu, C. R. (2004) · Modern Pathology · doi:10.1038/modpathol.3800334 · Cited by 145
A detailed deletion mapping of the short arm of chromosome 3 in sporadic renal cell carcinoma.
Yamakawa, K., Morita, R., Takahashi, E., Hori, T., Ishikawa, J., & Nakamura, Y. (1991) · PubMed · Cited by 142
Kim, H. A., Ling, B., & Ratner, N. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.2.862 · Cited by 140
Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules
Gregory, P. E., Gutmann, D. H., Mitchell, A., Park, S., Boguski, M. S., Jacks, T., Wood, D. L., Jove, R., & Collins, F. S. (1993) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01233074 · Cited by 140
Johnson, M. R., Look, A. T., DeClue, J. E., Valentine, M. B., & Lowy, D. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5539 · Cited by 140
Ferner, R. E. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201676 · Cited by 140
Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications
Gottfried, O. N., Viskochil, D. H., & Couldwell, W. T. (2009) · Neurosurgical FOCUS · doi:10.3171/2009.11.focus09221 · Cited by 139
Self-citationLélias, J.-M., Adra, C. N., Wulf, G. M., Guillemot, J.-C., Khagad, M., Caput, D., & Lim, B. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.4.1479 · Cited by 136
The interaction of Ras with GTPase‐activating proteins
Wittinghofer, A., Scheffzek, K., & Ahmadian, M. R. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00321-9 · Cited by 135
How does the Schwann cell lineage form tumors in NF1?
Carroll, S. L., & Ratner, N. (2008) · Glia · doi:10.1002/glia.20776 · Cited by 134
“…a mammalian Ras GTPase activating protein (GAP) known as p120RasGAP and the Saccharomyces cerevesiae Ras GAPs IRA1 and IRA2 (Ballester et al., 1990; Xu et al., 1990a); transfection of sequences encoding the neurofibromin Ras GAP-related domain (GRD) into IRA1- and IRA2-deficient yeast rescues…”
BackgroundFerner, R. E. (2010) · Practical Neurology · doi:10.1136/jnnp.2010.206532 · Cited by 134
Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes
Stephens, K. G., Kayes, L. M., Riccardi, V. M., Rising, M., Sybert, V., & Pagon, R. (1992) · Human Genetics · doi:10.1007/bf00197259 · Cited by 133
“With the recent cloning of the NF1 gene (Viskochil et al. 1990; Wallace et al. 1990; Xu et al. 1990 ), it will be interesting to determine if the majority of mutations occur at CpG sites that are often methylated or cluster at other sites that will provide clues to the mechanism of preferential NF1 mutation.”
BackgroundGutmann, D. H., Loehr, A., Zhang, Y., Kim, J., Henkemeyer, M. J., & Cashen, A. F. (1999) · Oncogene · doi:10.1038/sj.onc.1202829 · Cited by 133
“Sequence analysis demonstrated that a small central domain of neuro®bromin shares similarity with the catalytic domain of proteins involved in p21-ras regulation (Ballester et al., 1990; Martin et al., 1990; Xu et al., 1990a,b).”
BackgroundProtein prenylation: key to ras function and cancer intervention?
Khosravi‐Far, R., Cox, A. D., Kato, K., & Der, C. J. (1992) · PubMed · Cited by 130
Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice
Powers, J. F., EVINGER, M. J. Q., Tsokas, P., Bedri, S., Alroy, J., Shahsavari, M., & Tischler, A. S. (2000) · Cell and Tissue Research · doi:10.1007/s004410000290 · Cited by 130
“In order to evaluate the ability to express and regulate PNMT, additional blots were probed for PNMT (antibody TE-104; Eugene Tech, Allendale, N.J.), and PNMT levels were compared in control cultures and cultures incubated with dexamethasone (dexamethasone disodium phosphate; Merck, Sharp and Dohme Research Laboratori…”
MethodNeurofibromin controls macropinocytosis and phagocytosis in Dictyostelium
Bloomfield, G., Traynor, D., Sander, S. P., Veltman, D. M., Pachebat, J. A., & Kay, R. R. (2015) · eLife · doi:10.7554/elife.04940 · Cited by 126
“…Ras GTPase activating protein (RasGAP) Neurofibromin (NF1), a tumour suppressor that is mutated in the genetic disorder Neurofibromatosis type 1 (Xu et al., 1990), is a key regulator of both macropinocytosis and phagocytosis. eLife digest Dictyostelium amoebae are microbes that feed on bacteria…”
BackgroundViskochil, D. H., Cawthon, R., O'Connell, P., Xu, G., Stevens, J., Culver, M., Carey, J. C., & White, R. L. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.2.906-912.1991 · Cited by 129
“0 and would be highly beneficial if the intron genes continue to be The three genes together span approximately expressed to some degree in tissues in which NFI is exence within one intron of NFl (40); the 5' end pressed.”
BackgroundSelf-citationLing, B. C., Wu, J., Miller, S. J., Monk, K. R., Shamekh, R., Rizvi, T. A., deCourten-Myers, G., Vogel, K. S., DeClue, J. E., & Ratner, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.10.016 · Cited by 130
“B: Quantification of ligands present in nerve BTC BTC avg Ct GAPDH avg Ct Ct Ct Fold change W/T 31.94 0.02 25.46 0.49 6.48 0.49 0.00 0.49 1 (0.71–1.41) EGFR 27.90 0.02 27.76 0.15 5.14 0.15 1.34 0.15 2.53 (2.28–2.81) HBEGF HBEGF avg Ct GAPDH avg Ct Ct Ct Fold change W/T 31.42 0.05 27.61 0.50 3.81 0.50 0.00 0.60 1 (0.71…”
BackgroundInfluentialDasgupta, B., Yi, Y., Hegedűs, B., Weber, J. D., & Gutmann, D. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1842 · Cited by 128
“Within the central portion of neurofibromin is a 300–amino acid residue region which contains a Ras GTPaseactivating protein domain (5).”
BackgroundCharacterization of full‐length neurofibromin: tubulin inhibits Ras GAP activity.
Bollag, G. E., McCormick, F. P., & Clark, R. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05841.x · Cited by 128
NF1 Mutations Are Common in Desmoplastic Melanoma
Wiesner, T., Kiuru, M. H., Scott, S. N., Arcila, M. E., Halpern, A. C., Hollmann, T. J., Berger, M. F., & BUSAM, K. J. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000451 · Cited by 128
Soft‐tissue sarcomas in children and adolescents with neurofibromatosis type 1
Ferrari, A., Bisogno, G., Macaluso, A., Casanova, M., D’Angelo, P., Pierani, P., Zanetti, I., Alaggio, R., Cecchetto, G., & Carli, M. (2007) · Cancer · doi:10.1002/cncr.22533 · Cited by 127
“The gene involved in this genetic disorder is termed NF-1 and was cloned in 1990.(7,8) All individuals with NF1 have an NF-1 gene mutation.”
BackgroundRegulatory mechanisms for ras proteins
Downward, J. (1992) · BioEssays · doi:10.1002/bies.950140308 · Cited by 127
The Neurofibromatosis Type I Messenger RNA Undergoes Base-Modification RNA Editing
Skuse, G. R., Cappione, A., Sowden, M. P., Metheny, L. J., & Smith, H. C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.3.478 · Cited by 126
Malignant peripheral nerve sheath tumors
Gupta, G., & Maniker, A. H. (2007) · Neurosurgical FOCUS · doi:10.3171/foc.2007.22.6.13 · Cited by 125
Malignant Peripheral Nerve Sheath Tumor
Zhou, H., Coffin, C. M., Perkins, S. L., Tripp, S. R., Liew, M. A., & Viskochil, D. H. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200310000-00006 · Cited by 125
“The function of the NF1 gene product, neurofibromin, is to reduce cell signal transduction by accelerating inactivation of the proto-oncogene p21ras.(32,51,59) Mutations in NF1generally lead to increased ras signaling, and individuals with NF1 have an increased risk of developing both benign and malignant tumors, espe…”
BackgroundSelf-citationDasgupta, B. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4693-04.2005 · Cited by 125
“Consistent with the established function of the NF1 gene product (neurofibromin) in RAS inhibition (Ballester et al., 1990; Martin et al., 1990; Xu et al., 1990), OPGs also arise in Nf1 / mice as a result of dysregulated K-RAS activity in astrocytes (Dasgupta et al.”
BackgroundKurachi, H., Wada, Y., Tsukamoto, N., Maeda, M., KUBOTA, H. Y., Hattori, M., Iwaï, K., & Minato, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.28081 · Cited by 124
Olson, M. F., & Marais, R. (2000) · Seminars in Immunology · doi:10.1006/smim.2000.0208 · Cited by 124
Daston, M. M., & Ratner, N. (1992) · Developmental Dynamics · doi:10.1002/aja.1001950307 · Cited by 123
Küssel‐Andermann, P., & Frasch, M. (1995) · The Journal of Cell Biology · doi:10.1083/jcb.129.6.1491 · Cited by 122
“For instance, mutation of NF1, a GTPase-activating protein, appears to create a constitutive proliferative signal in neuronal tissues only, although the protein is expressed in other tissues as well (Xu et al., 1990; Daston and Ratner, 1992).”
Mast cells and the neurofibroma microenvironment
Staser, K. W., Yang, F., & Clapp, D. W. (2010) · Blood · doi:10.1182/blood-2009-09-242875 · Cited by 125
“and IRA2, converts active Ras from its GTP-bound state to its inactive guanine diphosphate (GDP)-bound state.(3,13,16,21,62,63) Loss of GAPs can induce neoplasia through increased cellular growth, proliferation, and migration.”
BackgroundWarrington, N. M., Woerner, B. M., Daginakatte, G., Dasgupta, B., Perry, A., Gutmann, D. H., & Rubin, J. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2220 · Cited by 121
Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms
Carroll, S. L. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0928-6 · Cited by 120
“However, this intrinsic GTPase activity is inefficient and, in isolation, cleaves GTP as a very low rate; GAPs such as IRA1 and IRA2 facilitate Ras inactivation by binding to Ras and enhancing its GTPase activity by several orders of magnitude.”
InfluentialRecent developments in neurofibromatosis type 1
Lee, M., & Stephenson, D. A. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3280895da8 · Cited by 120
Intramedullary Spinal Cord Tumors in Neurofibromatosis
Lee, M. W., Rezai, A. R., Freed, D. L., & Epstein, F. J. (1996) · Neurosurgery · doi:10.1097/00006123-199601000-00009 · Cited by 119
SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype
Pasmant, É., Sabbagh, A., Hanna, N., Masliah‐Planchon, J., Jolly, E. R., Goussard, P., Ballerini, P. F., Cartault, F., Barbarot, S., Landman‐Parker, J., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.065243 · Cited by 118
Abdominal Neoplasms in Patients with Neurofibromatosis Type 1: Radiologic-Pathologic Correlation
Levy, A. D., Patel, N. D., Dow, N. S., Abbott, R. M., Miettinen, M., & Sobin, L. H. (2005) · Radiographics · doi:10.1148/rg.252045176 · Cited by 115
Wang, W., Nyman, J. S., Ono, K., Stevenson, D. A., Yang, X., & Elefteriou, F. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr310 · Cited by 114
“Neurofibromin is a specific suppressor of p21-RAS, and mutations in this gene cause unsuppressed activation of RAS, leading to abnormal cell growth and differentiation and to the clinical features of NF1 (3).”
BackgroundFeldkamp, M. M., Lau, N. C., & Guha, A. (1999) · Oncogene · doi:10.1038/sj.onc.1203105 · Cited by 114
“GDP through an intrinsic GTPase activity, catalyzed by GTPase Activating Proteins (Ras-GAPs), predominantly p120-GAP and neuro®bromin, the protein product of the NF1 gene (Downward, 1992; Xu et al., 1990).”
BackgroundStaser, K. W., Yang, F., & Clapp, D. W. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132441 · Cited by 113
“Neurofibromin, which contains a highly-conserved GAP-related domain (GRD) with homology to the yeast gene products IRA1 and IRA2, logarithmically accelerates the intrinsic hydrolysis of active GTP-bound Ras to its GDP-bound state (47, 52, 65, 68, 76, 132).”
BackgroundInfluentialAmino acid management in cancer
Tsun, Z.-Y., & Possemato, R. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.08.002 · Cited by 120
Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
Yan, N., Ricca, C. S., Fletcher, J. A., Glover, T. W., Seizinger, B. R., & Manne, V. (1995) · PubMed · Cited by 112
Mouse Mutants and Cardiac Development
Rossant, J. (1996) · Circulation Research · doi:10.1161/01.res.78.3.349 · Cited by 111
IRA2, an upstream negative regulator of RAS in yeast, is a RAS GTPase-activating protein.
Tanaka, K., Lin, B. K., Wood, D. R., & Tamanoi, F. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.2.468 · Cited by 112
The role of p21ras in receptor tyrosine kinase signalling
Pronk, G. J. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90010-8 · Cited by 112
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma
Casey, D., Demko, S., Sinha, A. K., Mishra-Kalyani, P. S., Shen, Y. L., Khasar, S. G., Goheer, M. A., Helms, W. S., Pan, L., Xu, Y., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-5032 · Cited by 111
“Oropharyngeal pain 24 (48) 0 30 (41) 0 Paronychia(6) 24 (48) 3 (6) 35 (47) 7 (10)”
Maekawa, M., Li, S., Iwamatsu, A., Morishita, T., Yokota, K., Imai, Y., Kohsaka, S., Nakamura, S., & Hattori, S. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6879 · Cited by 111
Metadata
- Authors
- Xu, G., O'Connell, P., Viskochil, D., Cawthon, R., Robertson, M., Culver, M., Dunn, D., Stevens, J., Gesteland, R., White, R., & Weiss, R.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Utah (US)
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 1990-08
- Volume
- 62
- Issue
- 3
- Pages
- 599-608
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2159096148
- Cited by
- 1,095
- References
- 42
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 19 · 2023: 19 · 2022: 22 · 2021: 22 · 2020: 22 · 2019: 18 · 2018: 22 · 2017: 17 · 2016: 19 · 2015: 21 · 2014: 24 · 2013: 24 · 2012: 45
- FWCI
- 70.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- U.S. Department of Energy
- Topics
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- neurofibromatosis type 1, NF1 gene, GTPase-activating protein, Ras, open reading frames, cDNA cloning, cell growth regulation, protein homology
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Cattle, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 17, Cloning, Molecular, Genes, Humans, Information Systems, Molecular Sequence Data, Neurofibromatosis 1, Proteins, Sequence Homology, Nucleic Acid, Translocation, Genetic, Oligonucleotide Probes, Gene Library, Polymerase Chain Reaction, GTPase-Activating Proteins, ras GTPase-Activating Proteins, Neurofibromin 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review